Genomic Health expects to achieve double-digit revenue growth in FY19

The company said “In the Q1 we delivered more than 17% overall revenue growth and $13.0M in profit driven by significant growth across all key product areas. Our Q1 performance was very strong, based in part on the impact of the landmark TAILORx trial results, which are continuing to drive increased Oncotype DX Breast Recurrence Score test usage both in the U.S. and globally. We expect to achieve double-digit revenue growth for the year with continued growth across key products and look forward to the national reimbursement decision in Germany for the Oncotype DX breast cancer test.”
https://thefly.com/landingPageNews.php?id=2905275